comparemela.com

Latest Breaking News On - Bio contact - Page 2 : comparemela.com

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib

- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding.

Japan
Boston
Massachusetts
United-states
China
Genor-biopharma
Samantha-dale-strasser
Jack-bailey
Caitlin-brown
Research-triangle-park
Merck-digital-sciences-studio
Exchange-commission

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Florida
United-states
Boca-raton
New-york
Inmune-bio
David-moss
Company-phase
Inmune-bio-inc
Company-annual-report-on-form
Company-current-reports-on-form
Exchange-commission
Drug-administration

INmune Bio (INMB) Reports 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio (INMB) Reports 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-antonio
Texas
United-states
Inmune-bio
David-moss
Joshua-schoonover
Jason-nelson
Exchange-commission
Company-current-reports-on-form
Tho-company
Drug-administration
Nasdaq

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

Boca Raton, Florida, April 23, 2024  INmune Bio, Inc.  , a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight.

Boca-raton
Florida
United-states
San-antonio
Texas
Joshua-schoonover
Jason-nelson
Inmune-bio
David-moss
Nasdaq
Company-current-reports-on-form
Exchange-commission

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., April 10, 2024 BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the.

Vikram-bali
Linkedin
Bio-pharma-inc
Twitter
Nasdaq
Bridgebio-pharma-inc
Bio-pharma
Equity-plan
Nasdaq-listing-rule
Bridgebio-pharma
Bio-contact
Markets

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.